122 related articles for article (PubMed ID: 8105438)
1. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage.
Pupa SM; Ménard S; Morelli D; Pozzi B; De Palo G; Colnaghi MI
Oncogene; 1993 Nov; 8(11):2917-23. PubMed ID: 8105438
[TBL] [Abstract][Full Text] [Related]
2. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.
Pupa SM; Ménard S; Andreola S; Colnaghi MI
Cancer Res; 1993 Dec; 53(24):5864-6. PubMed ID: 7903196
[TBL] [Abstract][Full Text] [Related]
3. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
Langton BC; Crenshaw MC; Chao LA; Stuart SG; Akita RW; Jackson JE
Cancer Res; 1991 May; 51(10):2593-8. PubMed ID: 1673637
[TBL] [Abstract][Full Text] [Related]
4. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
5. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
6. The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3.
Alper O; Yamaguchi K; Hitomi J; Honda S; Matsushima T; Abe K
Cell Growth Differ; 1990 Dec; 1(12):591-9. PubMed ID: 1981143
[TBL] [Abstract][Full Text] [Related]
7. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
Fendly BM; Winget M; Hudziak RM; Lipari MT; Napier MA; Ullrich A
Cancer Res; 1990 Mar; 50(5):1550-8. PubMed ID: 1689212
[TBL] [Abstract][Full Text] [Related]
8. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
Bacus SS; Gudkov AV; Zelnick CR; Chin D; Stern R; Stancovski I; Peles E; Ben-Baruch N; Farbstein H; Lupu R
Cancer Res; 1993 Nov; 53(21):5251-61. PubMed ID: 8106145
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
11. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.
Christianson TA; Doherty JK; Lin YJ; Ramsey EE; Holmes R; Keenan EJ; Clinton GM
Cancer Res; 1998 Nov; 58(22):5123-9. PubMed ID: 9823322
[TBL] [Abstract][Full Text] [Related]
12. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
[TBL] [Abstract][Full Text] [Related]
13. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
[TBL] [Abstract][Full Text] [Related]
14. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells.
Perez-Torres M; Valle BL; Maihle NJ; Negron-Vega L; Nieves-Alicea R; Cora EM
Exp Cell Res; 2008 Oct; 314(16):2907-18. PubMed ID: 18687326
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry: a new approach for the molecular profiling of breast cancer.
Lostumbo A; Mehta D; Setty S; Nunez R
Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
[TBL] [Abstract][Full Text] [Related]
17. [Development of sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma].
Yu FZ; Sugano K; Ohkura H; Mori S
Rinsho Byori; 1991 Oct; 39(10):1087-92. PubMed ID: 1684826
[TBL] [Abstract][Full Text] [Related]
18. Colocalization of the p185HER2 oncoprotein and integrin alpha 6 beta 4 in Calu-3 lung carcinoma cells.
Campiglio M; Tagliabue E; Srinivas U; Pellegrini R; Martignone S; Ménard S; Colnaghi MI; Lombardi L; Marchisio PC
J Cell Biochem; 1994 Aug; 55(4):409-18. PubMed ID: 7962174
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
20. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
